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Abstract
Background: In the present investigation we compared blood epinephrine (EPI), norepinephrine (NE), free fatty acids 
(FFA) and glycerol concentrations in response to a capsaicinoid supplement or placebo in healthy adults before and 
after acute exercise.
Methods: Twenty subjects ingested a placebo or supplement (Capsimax™, OmniActive Health Technologies; 2 mg 
capsaicinoids in a microencapsulated matrix) with one week separating conditions. Fasting blood samples were 
collected during each visit; 30 minutes following a rest period and before placebo or supplement intake (Pre); 2 hours 
post intake (2 hr); one minute following the cessation of 30 minutes of exercise performed at 65% of maximal heart rate 
reserve (2.5 hr); 90 minutes following the cessation of exercise (4 hr). Heart rate (HR), systolic (SBP) and diastolic (DBP) 
blood pressure were recorded at all times.
Results: A time effect was noted for HR, SBP, and DBP (p < 0.05), with HR and SBP higher at 2.5 hr compared to Pre (due 
to exercise) and DBP lower at 2.5 hr compared to Pre. No interaction or condition effects were noted for EPI, NE, FFA, or 
glycerol (p > 0.05). However, a time effect was noted for all variables (p < 0.0001), with values higher than Pre at 2.5 hr 
for EPI and glycerol, at 2 hr and 2.5 hours for FFA, and at 2 hr, 2.5 hr, and 4 hr for NE (p < 0.05). In terms of percent 
change from Pre, glycerol was higher with Capsimax™ than for placebo at 4 hr (p = 0.011) and FFA was higher with 
Capsimax™ than for placebo at 2 hr (p = 0.025) and at 2.5 hr (p = 0.015).
Conclusion: Ingestion of low dose (2 mg) Capsimax™ was associated with an increase in blood FFA and glycerol at 
selected times post ingestion, as compared to placebo. However, Capsimax™ had no differing effect on EPI or NE 
compared to placebo. Lastly, no difference was noted in HR, SBP, or DBP between placebo and Capsimax™.
Background
The prevalence of obesity and overweight status is clearly
on the rise throughout the developed world, evidenced by
the nearly 400 million individuals currently classified as
obese [1,2], with an additional 1.6 billion classified as
overweight [2]. While lifestyle factors such as increased
physical activity [3] and modification of dietary intake [4]
are viewed as a first line method in both the prevention
and condition of obesity and obesity related illness, phar-
maceuticals [5] and dietary supplements [6] are often
used as an aid in body fat/weight loss. In relation to the
latter, many such supplements have little to no scientific
support in human subjects, while some have been
reported to cause ill-health [7]. This is especially true in
regards to the hemodynamic response observed with
many dietary supplements targeting weight/fat loss [8], a
real concern in particular for those who are hypertensive.
One nutritional agent with scientific support as an aid
to weight/fat loss is capsaicinoids. Capsaicinoids are the
major pungent, naturally occurring active compounds in
capsicum fruits such as hot chili peppers (genus capsi-
cum), with the most abundant forms being capsaicin (8-
methyl-N-vanillyl-6-nonenamide), dihydrocapsaicin, and
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nordihydrocapsaicin [9]. Approximately 3 mg of capsaici-
noids are present within 1 g of dried red pepper [10].
Capsaicinoids have been reported in the literature to
reduce ad libitum food intake [11-13], to increase ther-
mogenesis [10,14-16], and to increase lipolysis as mea-
sured via breath sample analysis [10,14,15,17]. Moreover,
epidemiological data describe an association between the
consumption of capsaicinoid containing foods and a
lower incidence of obesity [18]. This appears to occur
without any significant and prolonged effect on heart rate
or blood pressure [19].
In terms of lipolysis, capsaicinoids are an agonist of the
transient receptor potential vanilloid subfamily member
1 (TRPV1). This TRPV1 releases the substance P, which
in turn activates the postsynaptic receptor of substance P,
neurokinin-1. This activation of neurokin-1 results in an
increased activation of the sympathetic nervous system,
leading to the release of epinephrine (EPI) and norepi-
nephrine (NE) from adrenal gland [20]. Because both EPI
and NE interact with hormone sensitive lipase, an
increase in triglyceride degradation may be observed
with capsaicinoid intake, which may lead to an increase in
circulating free fatty acids (FFA) and glycerol [21].
While many authors have suggested an increase in
lipolysis following capsaicinoid intake [14,15], these stud-
ies have relied on the measurement of breath sample
analysis (e.g., respiratory exchange ratio) as a crude mea-
sure of substrate utilization. To our knowledge, no studies
using human subjects have determined fat oxidation by
including the measurements of blood FFA and glycerol
concentrations following capsaicinoid intake. Moreover,
no human studies have included the measurements of
blood EPI and NE concentrations following capsaicinoid
intake. Finally, due to the fact that many individuals use
nutritional supplements in conjunction with aerobic
exercise for fat loss purposes, we were also interested in
the combined effects of capsaicinoid treatment and exer-
cise on markers of lipolysis. Therefore, the purpose of the
present investigation was to compare blood EPI, NE, FFA,
and glycerol concentrations before and at selected times
through 4 hours post ingestion of a placebo or a capsaici-
noid supplement, with the addition of an acute exercise
bout. We hypothesized that the capsaicinoid supplement
would result in an increase in circulating catecholamines
and in markers of lipolysis compared to placebo.
Methods
Subjects
Young and healthy, exercise-trained men (n = 10) and
women (n = 10) participated in this investigation. All sub-
jects completed a detailed medical history and physical
activity questionnaire in order to determine eligibility. No
subject was a smoker, used smokeless tobacco products,
or had diagnosed cardiovascular or metabolic disease.
Men and women were considered to be exercise-trained,
as they performed combined aerobic and anaerobic exer-
cise for 7 ± 2 and 6 ± 2 hrs per week, respectively, for the
past several years. Subject descriptive characteristics are
presented in Table 1. All experimental procedures were
performed in accordance with the Helsinki Declaration.
The University of Memphis Human Subjects Committee
approved all experimental procedures, and subjects pro-
vided verbal and written consent prior to participating in
this study.
Table 1: Descriptive characteristics of 20 healthy adults
Variable Men
(n = 10)
Women
(n = 10)
P value
Age (yrs) 25.5 ± 1.2 23.9 ± 1.3 0.375
Height (cm) 175.2 ± 2.0 165.9 ± 1.4 0.002
Weight (kg) 77.4 ± 2.5 60.2 ± 3.9 0.002
BMI (kg·m-2) 25.2 ± 0.6 21.7 ± 1.1 0.01
Body fat (%)* 10.2 ± 1.1 21.1 ± 1.6 < 0.0001
Waist (cm) 82.9 ± 1.7 67.5 ± 1.9 < 0.0001
Hip (cm) 99.0 ± 1.4 96.4 ± 2.8 0.428
Waist:Hip 0.84 ± 0.01 0.70 ± 0.01 < 0.0001
Anaerobic Exercise (years) 8.3 ± 1.5 4.2 ± 1.0 0.035
Anaerobic Exercise (hours per week) 3.6 ± 0.5 1.4 ± 0.4 0.002
Aerobic Exercise (years) 5.1 ± 1.4 7.9 ± 2.2 0.282
Aerobic Exercise (hours per week) 3.8 ± 1.2 5.0 ± 1.1 0.484
Data are Mean ± SEM
* Determined from 7-site skinfold analysis use Lange calipers and Siri equationBloomer et al. Lipids in Health and Disease 2010, 9:72
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Conditions and Testing
All procedures described below were identical for both
test days (supplement and placebo). The dietary supple-
ment used in this investigation (Capsimax™; OmniActive
Health Technologies, Mumbai, India) included 100 mg of
encapsulated beadlets, standardized to 2% capsaicinoids,
of which 1.2-1.35% was capsaicin, 0.6-0.8% was dihydro-
capsaicin, and 0.1-0.2% was nordihydrocapsaicin. While
capsaicinoids are absorbed through the gastrointestinal
tract by a non-active process and then distributed to the
whole body via plasma [22], the supplement used in the
present investigation is coated to minimize pungency and
to avoid gastric irritation. It is specifically designed for
minimal release in stomach (up to a maximum of 15% of
capsaicinoids), but rather a release in the small intestine.
Dissolution studies performed by OmniActive Health
Technologies indicate a range of 60-75% of capsaicinoids
released by 4 hours post ingestion of the supplement,
when consumed on an empty stomach following an over-
night fast. For complete release of capsaicinoids, the time
of study would need to be extended beyond 6 hours.
While such a timeframe may be ideal and provide for the
most robust effects, we did not attempt this within the
current design due to the difficulty in having subjects fast
for such an extended period. Hence, the present study
only carried out measures through 4 hours post inges-
tion.
The placebo capsules were identical in appearance and
consisted of cellulose. Both the supplement and placebo
capsules were manufactured under GMP conditions
(Rubicon Research, Mumbai, India). The experiment was
conducted as a randomized, placebo controlled, double
blind, cross-over design. Subjects reported to the lab in a
12 hour fasted state and no food was consumed until all
testing was completed. However, water was allowed ad
libitum, and was measured and matched for both days of
testing (mean intake for men = 1360 mL; mean intake for
women = 691 mL).
As stated above, subjects reported to the lab in a fasted
state (12 hours), without caffeine consumption during the
past 12 hours. All testing was started by 0800 hours and
the time for each subject was matched for both visits.
Subjects were instructed not to exercise for the 48 hours
prior to each testing day. Women reported during the
first 7-9 days of their menstrual cycle in order to avoid
any potential influence of estradiol on our blood markers.
Upon arrival to the lab, subjects rested quietly for 30 min-
utes in a seated position. Following this quiet rest period,
heart rate (via monitor) and blood pressure (via ausculta-
tion) were measured and a blood sample was obtained
(Pre). Subjects were then provided their assigned condi-
tion (supplement or placebo) and ingested this in the
presence of an investigator. Three additional blood sam-
ples were obtained from subjects during each visit, as fol-
lows: The second blood sample was collected 2 hours
post intake, during which time subjects rested quietly (2
hr). Subjects then exercised on a treadmill for 30 minutes
at an intensity equal to 65% of maximal heart rate reserve
(A familiarization session was provided for this exercise
bout during the initial screening visit). A third blood
sample was taken within one minute of the cessation of
exercise (2.5 hr). Subjects then rested quietly and a fourth
blood sample was taken 90 minutes following the cessa-
tion of exercise (4 hr). Other than for the 30 minute exer-
cise bout, subjects remained inactive in the laboratory
during the entire 4.5 hour test period. Heart rate (HR),
systolic (SBP), and diastolic (DBP) blood pressure were
measured prior to each blood draw, and also at 1 hr and 3
hr post intake.
In addition to biochemical measures as described
below, breath samples were collected from subjects dur-
ing five-minute periods at all blood collection times, in
addition to other times periodically during the four hour
post ingestion measurement period. This was done in an
attempt to determine if isolated breath sample collection,
as opposed to continuous breath collection, could prove
to be a useful methodology for assessing metabolic rate,
kilocalorie expenditure, and substrate utilization mea-
sured via respiratory exchange ratio (RER) following cap-
saicinoid intake. The measurements were performed
using indirect calorimetry via breath-by-breath collection
(SensorMedics Vmax 229 metabolic system; Yorba Linda,
CA). All gas collection took place in a temperature and
humidity controlled laboratory, and both the flow sensor
and gas analyzers were calibrated prior to data collection.
Total oxygen consumption (L·min-1) was determined and
total kilocalorie expenditure was estimated from this
value. The RER was determined from gas collection
(CO2/O2), and used as a crude measure of substrate utili-
zation. Our results for these measures indicated that a
sporadic collection period (i.e., 5-minute intervals) did
not capture all potential changes in the above mentioned
gas variables. Hence, these data are not presented within
this manuscript. Future studies involving capsaicinoids
should continue to use a continuous method of breath
sample collection.
Blood Collection and Biochemistry
A total of four venous blood samples (7 mL per draw)
were taken from subjects' forearm via needle and Vacu-
tainer®. Blood was immediately processed in a refriger-
ated centrifuge to obtain plasma (4°C for 15 min at
2000×g). Plasma samples were then stored in multiple ali-
quots at -80°C. All assays were performed on first thaw
within four weeks of sample collection. Norepinephrine
and EPI were determined using an enzyme linked immu-
nosorbent assay (2-CAT ELISA, BA 10-1500; Rocky
Mountain Diagnostics) following the instructions of theBloomer et al. Lipids in Health and Disease 2010, 9:72
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manufacturer (Labor Diagnostika Nord GmbH & Co.
KG). In this competitive ELISA, NE and EPI are extracted
by using a cis-diol-specific affinity gel, acylated, and then
derivitized enzymatically. The coefficient of variation
(CV) for NE and EPI in our lab is < 9% and < 8%, respec-
tively. Free fatty acids were determined using the Free
Fatty Acid Quantification Kit (K612-100) following the
instructions of the manufacturer (BioVision). The CV for
FFA in our lab is < 7%. Glycerol was determined using the
Free Glycerol Determination Kit (FG0100) and Glycerol
Standard (G7793), following the instructions of the man-
ufacturer (Sigma Aldrich). The CV for glycerol in our lab
is < 8%.
Diet and Physical Activity
During the 24 hours before each test day, subjects con-
sumed prepackaged meal replacement drinks (protein-
rich ready-to-drink shake) and food bars. These con-
tained a mix of protein, carbohydrate, and fat. Subjects
w e r e  e a c h  p r o v i d e d  w i t h  3  s h a k e s  a n d  4  b a r s  a n d
instructed to consume as many of these as they desired,
while consuming no other food or calorie containing
drinks. The amount consumed during the day preceding
the first test day was duplicated during the day preceding
the second test day. The mean intake for men was 3
shakes and 4 bars, while for women this was 2 shakes and
2.5 bars. These amounts provided approximately 2000
kilocalories to men and 1250 kilocalories to women.
Statistical Analysis
Biochemical data were analyzed using a 2 (condition) × 4
(time) analysis of variance (ANOVA). ANOVA was also
performed for change from baseline (Pre) for all blood-
borne variables. Condition and time were treated as fixed
factors and subjects nested within sequence were treated
as a random factor. Heart rate and blood pressure data
were analyzed using a 2 (condition) × 6 (time) ANOVA.
Statistical significance was set at p ≤ 0.05.
Results
All subjects successfully completed both test days. The
capsaicinoid supplement provided at the stated dosage
was well tolerated, with no observed side effects related
to gastric upset or discomfort.
Hemodynamic Data
No condition x time interaction or condition effect was
noted for HR, SBP, or DBP (p > 0.05). However, a time
effect was noted for all variables (p < 0.05), with HR and
SBP higher at 2.5 hr compared to Pre (due to the acute
exercise bout) and DBP lower at 2.5 hr compared to Pre
(due to the acute exercise bout). Hemodynamic data are
presented in Table 2.
Biochemical Data
No interaction or condition effects were noted for EPI,
NE, FFA, or glycerol (p > 0.05). However, a time effect
was noted for all variables (p < 0.0001), with values higher
than Pre at 2.5 hr for EPI and glycerol, at 2 hr and 2.5
hours for FFA, and at 2 hr, 2.5 hr, and 4 hr for NE (p <
0.05). Data for EPI and NE are presented in Table 3 and
data for FFA and glycerol are presented in Table 4. When
investigating the percent change data, glycerol for Capsi-
max™ was significantly higher than for placebo at 4 hr (p
= 0.011). Also, FFA for Capsimax™ was significantly
higher than for placebo at 2 hr (p = 0.025) and at 2.5 hr (p
= 0.015). Data are presented in Table 5.
Discussion
Our data indicate that ingestion of low dose capsaicinoid
supplement can increase plasma FFA (2 hr and 2.5 hr)
and glycerol (4 hr) concentrations compared to a placebo
in a sample of healthy adults. There was no statistically
significant effect of the capsaicinoid supplement on EPI
or NE concentration compared to placebo. Finally, no sta-
tistically significant increase in HR, SBP, or DBP was
noted with capsaicinoid supplementation (Table 2).
Several prior studies using human subjects have mea-
sured lipolysis using breath sample analysis rather than
actual blood markers of triglyceride degradation. This
former measure of lipolysis includes breath gas sample
analysis using indirect calorimetry [23], or more specifi-
cally, a measure of the respiratory exchange ratio (VCO2/
VO2). While this is a widely used tool in the study of met-
abolic rate and caloric expenditure, we wanted to include
a more specific approach by including the measurement
of blood FFA and glycerol concentrations. While many
previous studies have used dosages of capsaicinoids rang-
ing from 3 mg [16] to over 150 mg [24] while noting
mixed findings for increased lipolysis, our data support
the use of a very low dosage of capsaicinoids (2 mg) to
increase FFA and glycerol concentrations. It is possible
that a higher dosage of our specific capsaicinoid supple-
ment would promote more dramatic effects. It is also
possible, based on dissolution studies of the Capsimax™,
that a longer time course of measurement may have been
associated with more profound effects. Further research
is necessary to test these hypotheses.
Previous studies have noted an increase in lipolysis fol-
lowing capsaicinoid intake [14,15], suggesting that this
agent may aid in body weight/fat loss. However, regard-
less of the acute effects of capsaicinoids in terms of the
lipolytic effects, the more important question pertains to
the long-term effect of capsaicinoid condition on body
weight/fat loss. A few studies have addressed this issue,
noting greater fat oxidation during a 3-month weight
maintenance phase (preceded by a 4-week very low calo-Bloomer et al. Lipids in Health and Disease 2010, 9:72
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rie diet) when subjects received 135 mg capsaicin/day
[15]. Despite this finding, no difference in weight regain
was noted between capsaicin and placebo conditions.
Snitker and colleagues had subjects ingest 6 mg/day of
non-pungent capsinoids or a placebo for a period of 12
weeks and noted minimal difference between conditions
in weight loss, body fat loss (statistically significant but of
little physiological relevance), and fat oxidation [25]. In
opposition to these reports, a significant reduction in vis-
ceral fat weight has been noted when capsaicin contain-
ing diets were fed to rodents [26]. Taken together, it is
difficult to state with confidence the physiological mean-
ing behind our noted increase in FFA (and to a lesser
extent glycerol) as related to weight/fat loss over time. It
is certainly possible that such an increase in lipolysis may
be maintained following chronic intake of capsaicinoid
supplementation, and be persistent for several hours
throughout the day. If so, it can be hypothesized that such
supplementation may indeed result in a significant effect
o n  b o d y  w e i g h t / f a t  l o s s  o v e r  t i m e .  O f  c o u r s e ,  f u t u r e
investigations are needed to support these hypotheses.
Finally, our data corroborate previous findings of
increased fatty acid release in healthy adults [27-29], as
indicated by our 2 and 2.5 hour sample analysis (Table 4).
Our objective in the present study was to investigate the
effect of a standard dosage of capsaicinoid (that typically
consumed within an over-the-counter dietary supple-
ment) in healthy adults, regardless of body weight. How-
Table 2: Hemodynamic data for healthy adults consuming Capsimax™ and placebo in a randomized cross-over design
Variable Pre 1 hr 2 hr
(pre-ex)
2.5 hr
(1 min post ex)
3 hr
(30 min post ex)
4 hr
(90 min post ex)
HR (bpm)
Capsimax™
58 ± 12 57 ± 11 58 ± 11 115 ± 17* 73 ± 14 65 ± 15
HR (bpm)
Placebo
60 ± 12 57 ± 11 58 ± 13 114 ± 14* 73 ± 14 65 ± 13
SBP (mmHg)
Capsimax™
112 ± 8 114 ± 8 115 ± 11 140 ± 16* 115 ± 8 113 ± 12
SBP (mmHg)
Placebo
112 ± 11 114 ± 11 116 ± 10 141 ± 16* 112 ± 11 111 ± 9
DBP (mmHg)
Capsimax™
72 ± 7 72 ± 6 72 ± 7 64 ± 10* 67 ± 7 70 ± 8
DBP (mmHg)
Placebo
71 ± 10 70 ± 7 70 ± 9 64 ± 10* 66 ± 8 68 ± 8
Data are Mean ± SD
No condition x time interaction or condition effect was noted for HR, SBP, or DBP (p > 0.05).
*A time effect was noted for all variables (p < 0.05); HR and SBP higher than Pre at 2.5 hr; DBP lower than Pre at 2.5 hr.
HR-heart rate; SBP-systolic blood pressure; DBP-diastolic blood pressure
Table 3: Blood catecholamine data for healthy adults consuming Capsimax™ and placebo in a randomized cross-over 
design
Variable Pre 2 hr
(pre-ex)
2.5 hr
(1 min post ex)
4 hr
(90 min post ex)
Epinephrine (pg·mL-1)
Capsimax™
41.54 ± 33.56 40.09 ± 29.83 69.34 ± 43.75 * 45.36 ± 39.36
Epinephrine (pg·mL-1)
Placebo
37.65 ± 27.16 36.54 ± 21.31 65.08 ± 51.10 * 34.49 ± 22.12
Norepinephrine (pg·mL-1)
Capsimax™
264.90 ± 132.66 378.63 ± 210.31** 491.08 ± 211.54** 440.10 ± 220.34 **
Norepinephrine (pg·mL-1)
Placebo
242.03 ± 157.63 326.84 ± 185.89** 553.53 ± 200.58** 344.61 ± 210.45**
Data are Mean ± SD
No interaction or condition effects were noted for EPI or NE (p > 0.05).
* A time effect was noted for EPI (p < 0.0001); values higher than Pre at 2.5 hr.
** A time effect was noted for NE (p < 0.0001); values higher than Pre at 2 hr, 2.5 hr, and 4 hr.Bloomer et al. Lipids in Health and Disease 2010, 9:72
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ever, future studies may provide a dosage based on kg
body weight rather than a standard dosage, in an attempt
to more specifically delineate potential differences in the
physiological effects of capsaicinoid supplementation in
adult subjects.
In conclusion, we report that a low dose capsaicinoid
supplement can increase plasma FFA concentrations and
glycerol compared to a placebo. This finding is observed
at 2 to 2.5 hr for FFA and 4 hr for glycerol post ingestion
of the supplement. The supplement had no statistically
significant effect on blood EPI or NE concentration, or on
HR, SBP, or DBP. Finally, these data support the well-doc-
umented finding of increased fatty acid release and glyc-
erol in response to an acute exercise bout. Further study
is needed to determine if more pronounced effects of
capsaicinoid intake can be observed using a longer time
course of measurement and/or a higher dosage of treat-
ment, with and without acute exercise. More importantly,
the chronic effects of Capsimax™ on weight/fat loss
require investigation.
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